What is Castle Biosciences's D&A?

Castle Biosciences (CSTL) reported D&A of $2.23M in Q1 2026.

How has Castle Biosciences's D&A changed year-over-year?

Castle Biosciences's D&A decreased by 92.1% year-over-year, from $28.33M to $2.23M.

What is the long-term trend for Castle Biosciences's D&A?

Over 4 years (2021 to 2025), Castle Biosciences's D&A has grown at a 105.4% compound annual growth rate (CAGR), from $1.96M to $34.84M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Castle Biosciences CSTL D&A

D&A at other companies

Labcorp HoldingsLH

$75.6M+8.6%

VeracyteVCYT

$5.43M+1.3%

Fulgent Genetics, Inc.FLGT

$2.03M+2.1%

Adaptive BiotechnologiesADPT

$419K0.0%

Quest DiagnosticsDGX

$37M-5.1%

Segments

By segment

See full

Reportable Segment$3.93M-86.8%

Other financials

Income statement

See full

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

See full

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

See full

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

See full

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

See full

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

See full

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's D&A?: Castle Biosciences (CSTL) reported D&A of $2.23M in Q1 2026.
How has Castle Biosciences's D&A changed year-over-year?: Castle Biosciences's D&A decreased by 92.1% year-over-year, from $28.33M to $2.23M.
What is the long-term trend for Castle Biosciences's D&A?: Over 4 years (2021 to 2025), Castle Biosciences's D&A has grown at a 105.4% compound annual growth rate (CAGR), from $1.96M to $34.84M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.